The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1
Open accessAbstract
BACKGROUND AND PURPOSE: Cardiotoxicity is an important side effect of the treatment of a malignant tumor with Doxorubicin. Currently, decreasing the dosage of Doxorubicin to alleviate the side effects on cardiac function is the common method to deal with the cardiotoxicity induced by Doxorubicin. The present study aims to investigate the therapeutic effects of Roflumilast on Doxorubicin-induced inflammation and cellular senescence, as well as the potential mechanism in H9c2 myocardial cells. METHODS: The injured cardiac cell model was established by incubation with 5 μmol/L Doxorubicin. MTT was used to evaluate the cell viability of treated H9c2 cardiac cells. The expression of 4-HNE was determined using an immunofluorescence assay. The gene expression levels of IL-17, IL-6, TNF-α, IL-4, PAI-1, p21, and SIRT1 were evaluated using qRT-PCR and the protein levels of Gpx4, PAI-1, p21, and SIRT1 were determined using Western blot analysis. Secretions of IL-17, IL-6, TNF-α, IL-4, CK-MB, and cTnI were measured using ELISA. Cellular senescence was assessed using SA-β-Gal staining. Si-RNA technology was used to knockdown the expression of SIRT1 in H9c2 cardiac cells. RESULTS: Cell viability of H9c2 cardiac cells was significantly inhibited by Doxorubicin but rescued by Roflumilast. The upregulated 4-HNE and downregulated Gpx4 were reversed by Roflumilast. The secretions of IL-6 and IL-17 were promoted by Doxorubicin and suppressed by Roflumilast. The increased SA-β-Gal staining induced by Doxorubicin was inhibited by Roflumilast. P21 and PAI-1 were significantly upregulated and SIRT1 was greatly downregulated by Doxorubicin, all of which were reversed by Roflumilast. The anti-senescent effect of Roflumilast was abolished by knocking down SIRT1. CONCLUSION: Roflumilast might attenuate Doxorubicin-induced inflammation and cellular senescence in cardiomyocytes by upregulating SIRT1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Doxorubicin-induced senescence in H9c2 myocardial cells results in increased expression of 4-HNE and GPX4, decreased SIRT1 expression, and heightened levels of pro-inflammatory cytokines (IL-6, IL-17, and TNF-α), while the anti-inflammatory cytokine IL-4 is reduced.
“In addition, doxorubicin-induced senescence in H9c2 myocardial cells results in increased expression of 4-HNE and GPX4, decreased SIRT1 expression, and heightened levels of pro-inflammatory cytokines (IL-6, IL-17, and TNF-α), while the anti-inflammatory cytokine IL-4 is reduced.291–293”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [291]
Split into 2 atoms — 1 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
Feedback between p21 and reactive oxygen production is necessary for cell senescence
Passos, J. F., Nelson, G., Wang, C., Richter, T., Simillion, C., Proctor, C. J., Miwa, S., Olijslagers, S., Hallinan, J., Wipat, A., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.5 · Cited by 1,019
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 864
Wang, Y., Xu, C.-F., Liu, Y.-J., Mao, Y.-F., Lv, Z., Li, S.-Y., Zhu, X.-Y., & Jiang, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477112 · Cited by 825
An overview of doxorubicin formulations in cancer therapy
Rivankar, S. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.139267 · Cited by 749
Redox regulation of SIRT1 in inflammation and cellular senescence
Hwang, J.-W., Yao, H., Caito, S., Sundar, I. K., & Rahman, I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.015 · Cited by 503
Sirtuin signaling in cellular senescence and aging
Lee, S.-H., Lee, J.-H., Lee, H., & Min, K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.290 · Cited by 447
Keravis, T. M., & Lugnier, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01729.x · Cited by 408
Myocyte apoptosis in heart failure
VANEMPEL, V., Bertrand, A., Hofstra, L., Crijns, H. J. G. M., Doevendans, P. A., & Windt, L. J. D. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.04.012 · Cited by 374
Hatzelmann, A., Morcillo, E. J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., Schudt, C., & Tenor, H. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.03.011 · Cited by 324
Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Koleini, N., & Kardami, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16944 · Cited by 308
Maejima, Y., Adachi, S., Ito, H., Hirao, K., & Isobe, M. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00358.x · Cited by 223
Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy
Hsu, C.-H., Altschuler, S. J., & Wu, L. F. (2019) · Cell · doi:10.1016/j.cell.2019.05.041 · Cited by 181
Obesity Induces Signs of Premature Cardiac Aging in Younger Patients
Niemann, B., Chen, Y., Teschner, M., Li, L., Silber, R., & Rohrbach, S. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.040 · Cited by 180
Cyclic Adenosine Monophosphate Phosphodiesterase Type 4 Protects Against Atrial Arrhythmias
Molina, C. E., Leroy, J., Richter, W., Xie, M., Scheitrum, C., Lee, I.-O., Maack, C., Rücker‐Martin, C., Donzeau‐Gouge, P., Verde, I., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.060 · Cited by 142
Polyphenols, autophagy and doxorubicin-induced cardiotoxicity
Shabalala, S. C., Muller, C. J. F., Louw, J., & Johnson, R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.05.003 · Cited by 140
Mata, M. (2005) · Thorax · doi:10.1136/thx.2004.025692 · Cited by 137
McGregor, E., & Dunn, M. J. (2006) · Circulation Research · doi:10.1161/01.res.0000201280.20709.26 · Cited by 130
Ruan, Y., Dong, C., Patel, J. D., Duan, C., Wang, X., Wu, X., Cao, Y., Pu, L., Lu, D., Shen, T., et al. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373937 · Cited by 122
Takahashi, T., Tang, T., Lai, N. C., Roth, D. M., Rebolledo, B. J., Saito, M. H., Lew, W. Y. W., Clopton, P., & Hammond, H. K. (2006) · Circulation · doi:10.1161/circulationaha.106.632513 · Cited by 106
The TGF-β1/p53/PAI-1 Signaling Axis in Vascular Senescence: Role of Caveolin-1
Samarakoon, R., Higgins, S. P., Higgins, C. E., & Higgins, P. J. (2019) · Biomolecules · doi:10.3390/biom9080341 · Cited by 104
Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain
El-Agamy, S. E., Abdel‐Aziz, A. K., Esmat, A., & Azab, S. S. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03827-0 · Cited by 101
A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence
Ghosh, A. K., Rai, R., Park, K. E., Eren, M., Miyata, T., Wilsbacher, L. D., & Vaughan, D. E. (2016) · Oncotarget · doi:10.18632/oncotarget.12494 · Cited by 95
Cardiotoxicity of Anticancer Therapeutics
Dong, J., & Chen, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00009 · Cited by 95
Kwak, H. J., Park, K., Choi, H., Chung, K., Lim, H., & Park, H. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.12.011 · Cited by 89
Testosterone Antagonizes Doxorubicin‐Induced Senescence of Cardiomyocytes
Altieri, P., Barisione, C., Lazzarini, E., Garuti, A., Bezante, G. P., Canepa, M., Spallarossa, P., Tocchetti, C. G., Bollini, S., Brunelli, C., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002383 · Cited by 86
The heart failure epidemic: magnitude of the problem and potential mitigating approaches
Massie, B. M., & Shah, N. B. (1996) · Current Opinion in Cardiology · doi:10.1097/00001573-199605000-00001 · Cited by 71
Kilic Eren, M., Kilincli, A., & Eren, Ö. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124837 · Cited by 68
Wu, Z., Zhao, X., Miyamoto, A., Zhao, S., Liu, C., Zheng, W., & Wang, H. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2019.1577467 · Cited by 65
From trends to transformation: where cardio-oncology is to make a difference
Herrmann, J. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz781 · Cited by 59
Liu, M., Shan, J., Li, J., Zhang, Y., & Lin, X.-L. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3437 · Cited by 56
Dallons, M., Schepkens, C., Dupuis, A., Tagliatti, V., & Colet, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00079 · Cited by 46
Chapman, R. W., House, A., Jones, H., Richard, J., Celly, C. S., PRELUSKY, D. B., Ting, P. C., Hunter, J. C., Lamca, J., & Phillips, J. E. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.074 · Cited by 45
Martínez, D. E., Borniego, L., Battchikova, N., Aro, E., Tyystjärvi, E., & GUIAMET, J. J. (2014) · Journal of Experimental Botany · doi:10.1093/jxb/eru409 · Cited by 44
Oncogenic ras induces premature senescence in endothelial cells: role of p21Cip1/Waf1
Spyridopoulos, I., Isner, J. M., & Losordo, D. W. (2002) · Basic Research in Cardiology · doi:10.1007/s003950200001 · Cited by 42
PDE 4 in the human heart – major player or little helper?
Thomas Eschenhagen, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12168 · Cited by 40
The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction
Dolinsky, V. W. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0316 · Cited by 37
Xin, W., Lu, X., Li, X., Niu, K., & Cai, J.-M. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00197 · Cited by 34
New therapeutic options in the management of COPD – focus on roflumilast
Antoniu, S. A. (2011) · International Journal of COPD · doi:10.2147/copd.s7336 · Cited by 31
Wohlsen, A., Hirrle, A., Tenor, H., Marx, D., & Beume, R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.005 · Cited by 18
EnayetAllah, A. E., Puppala, D., Ziemek, D., Fischer, J. E., Kantesaria, S., & Pletcher, M. T. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-46 · Cited by 14
Ischemic preconditioning reduces apoptosis in open heart surgery
Rachmat, J., Sastroasmoro, S., Suyatna, F. D., & Soeyono, G. (2014) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/0218492313481223 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and aging: signaling pathways and intervention therapies
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01502-8 · Cited by 1,443
Cellular Senescence in Cardiovascular Diseases: A Systematic Review
Hu, C., Zhang, X., Teng, T., Ma, Z., & Tang, Q. (2022) · Aging and Disease · doi:10.14336/ad.2021.0927 · Cited by 184
Role of acetylation in doxorubicin-induced cardiotoxicity
Li, D., Yang, Y., Wang, S., He, X., Liu, M., Bai, B., Tian, C., Sun, R., Yu, T., & Chu, X. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102089 · Cited by 141
Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem
Evangelou, K., Vasileiou, P. V. S., Papaspyropoulos, A., Hazapis, O. G., Petty, R., Demaria, M., & Gorgoulis, V. G. (2022) · Physiological Reviews · doi:10.1152/physrev.00007.2022 · Cited by 124
Packer, M. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.004 · Cited by 73
Al-Qahtani, W. H., Alshammari, G. M., Ajarem, J. S., Al-Zahrani, A. Y., Alzuwaydi, A., Eid, R. A., & Yahya, M. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112594 · Cited by 64
Therapeutic opportunities for senolysis in cardiovascular disease
Sweeney, M. D., Cook, S. A., & Gil, J. (2022) · FEBS Journal · doi:10.1111/febs.16351 · Cited by 54
Farid, H. A., Sayed, R. H., El-Shamarka, M. E.-S., Abdel‐Salam, O. M. E., & Sayed, N. S. E. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01305-x · Cited by 52
Liao, W., Rao, Z., Wu, L., Chen, Y., & Li, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850053 · Cited by 43
Wang, Y., Zhao, R., Wu, C., Liang, X., He, L., Wang, L., & Wang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111320 · Cited by 33
Alherz, F. A., Negm, W. A., El-Masry, T. A., Elmorshedy, K. E., & El-Kadem, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115010 · Cited by 31
Li, X. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116504 · Cited by 26
Abukhalil, M. H., Al‐Alami, Z. M., Alfwuaires, M. A., Imran, M., Aladaileh, S. H., & Althunibat, O. Y. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-09962-w · Cited by 22
Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies
Sun, Y., Xiao, L., Chen, L., & Wang, X. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07673-6 · Cited by 21
Fawzy, M. N., El-Haleim, E. A. A., Zaki, H. F., Salem, H. A., & El‐Sayed, R. M. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123488 · Cited by 19
Protective effects and mechanisms of lycorine against adriamycin-induced cardiotoxicity
Wang, Z., Chen, Y., Gu, M., Wu, Z. B., Ding, B., Yang, W., Wu, X., Wang, C., Gao, X., Yang, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154178 · Cited by 18
Gomaa, A. A., Farghaly, H. S. M., Ahmed, A. M., & Hemida, F. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109927 · Cited by 17
Li, X., Sun, T., Liu, J., Wei, S., Yang, Y., Liu, J., Zhang, B., & Li, W. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155046 · Cited by 15
Self-citationRecent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
Wang, T., Ma, Y., Gao, S., Zhang, W., Han, D. G., & Cao, F. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411336 · Cited by 15
Zhang, Y., Zhang, D., Meng, T., Tian, P., Chen, J., Liu, A., Zheng, Y., & Su, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111151 · Cited by 9
Zhao, N., Wu, M., Velu, P., Vijayalakshmi, A., & Zhang, J. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073358649241128053921 · Cited by 6
Liao, B., & Zhongyuan, H. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12001 · Cited by 6
Refaie, M. M. M., Ibrahim, M. F. G., Fawzy, M. A., Abdel‐Hakeem, E. A., Rahman, E. S. M. A. E., Zenhom, N. M., & Shehata, S. (2023) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2023.2222228 · Cited by 4
Aqueous Extract of Andrographis paniculata Ameliorates Cardiotoxicity Induced by Doxorubicin in vivo
Wang, H., Yu, X., Xun, Z., & Wu, Y. (2022) · International Journal of Pharmacology · doi:10.3923/ijp.2022.466.474 · Cited by 3
4-Deoxy-ε-Pyrromycinone: A Promising Drug/Lead Compound to Treat Tumors
Zhang, J., Sang, X., Yuan, Y., Shen, J., Fang, Y., Qin, M., Zheng, H., & Zhu, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s461594 · Cited by 3
NADPH Oxidases in Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Therapeutic Approaches
Adhab, A. H., Altalbawy, F. M. A., Mahdi, M. S., Baldaniya, L., Omar, T. M., Ganesan, S., Juneja, B., Pathak, P. K., Mansoor, A. S., Radi, U. K., et al. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-09976-4 · Cited by 2
Elsharab, A., Nooh, M. Z., Matard, R. S. A. E.-M., Mostafa, T. M., & El‐Afify, D. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s548285 · Cited by 1
Cellular Senescence in Heart Failure: A Review
Krauz, K., Czarzasta, K., Bugajewski, M., Momot, K., Wojciechowska, M., & Cudnoch‐Jędrzejewska, A. (2026) · Journal of Cellular Physiology · doi:10.1002/jcp.70136 · Cited by 1
Ezeani, C., Beshel, J. A., Okon, I. A., Inyang, E. G., & Owu, D. U. (2023) · PubMed Central · doi:10.22038/ijbms.2023.68651.15019 · Cited by 1
Wang, Z., Liu, X., Hu, S., Geng, S., Yang, D., Zhang, K., Li, X., Zheng, B., Zhu, X., & Sun, Y. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71347
P2Y12-AMPKα2 signaling contributes to cardiomyocyte senescence in doxorubicin-induced heart failure
Niu, Q., Wang, H. W., Zhao, M., Zhang, H., Hao, R., Liu, P., Guo, L., Chen, B., Xi, Y., Li, P., et al. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05593-z
Mechanisms of Doxorubicin-Induced Cardiac Senescence and Potential Therapeutic Strategies
Bai, Y., Yang, W., Wang, Z., Yang, Q., Zhang, Z., Liu, J., Qi, Y., & Liu, D. (2026) · Biomolecules · doi:10.3390/biom16081180
Self-citation
Metadata
- Authors
- Zhang, S., Wu, P., Liu, J., Du, Y., & Yang, Z.
- Affiliations
- Soochow University (CN)
- Jiangsu Province Hospital (CN)
- Corresponding author
- Yang, Zhijian
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-01
- Volume
- Volume 15
- Pages
- 87-97
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC7810683
- OpenAlex
- W3119152115
- Cited by
- 32
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 2 · 2023: 12 · 2022: 7 · 2021: 2
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (81441011, 81170102, 81670328)
- Government of Jiangsu Province
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- roflumilast, doxorubicin cardiotoxicity, SIRT1, cellular senescence, inflammation, cardiomyocytes, H9c2 cells, 4-hydroxynonenal, GPX4, interleukin-6, IL-17, p21, plasminogen activator inhibitor-1, cardioprotection, PPARδ agonist, oxidative stress
- MeSH terms
- Aminopyridines, Animals, Benzamides, Cells, Cultured, Cyclopropanes, Doxorubicin, Inflammation, Cellular Senescence, Myocytes, Cardiac, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
